Lenalidomide revenue dependency
Significant portion of U.S. growth attributed to lenalidomide; agreement ends January 2026, creating uncertainty beyond.
DRREDDY / Q1-FY24 / risks
Keep the risk register visible.
Dr. Reddy's Laboratories · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Russia market volatility
Russia business grew 77% but on a low base; currency and geopolitical risks remain high.
India innovation execution risk
Top-5 aspiration relies on signing and commercializing multiple innovative products; timeline and uptake uncertain.
Price erosion normalization in U.S.
Current lower price erosion may be temporary; management noted model hasn't changed, implying potential reversion.